Search: L773:1935 5548 OR L773:0149 5992
> (2000-2004) >
Beneficial effects ...
-
Alvarsson, MKarolinska Institutet
(author)
Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients
- Article/chapterEnglish2003
Publisher, publication year, extent ...
-
American Diabetes Association,2003
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:liu-25458
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-25458URI
-
https://doi.org/10.2337/diacare.26.8.2231DOI
-
https://lup.lub.lu.se/record/116971URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:1956174URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
OBJECTIVE - To evaluate whether treatment with insulin in recently diagnosed type 2 diabetes is advantageous compared with glibenclamide treatment. RESEARCH DESIGN AND METHODS - ▀-Cell function, glycemic control, and quality of life were monitored over 2 years in 39 patients with islet cell antibody-negative type 2 diabetes diagnosed 0-2 years before inclusion in a Swedish multicenter randomized clinical trial. Patients were randomized to either two daily injections of premixed 30% soluble and 70% NPH insulin or glibenclamide (3.5-10.5 mg daily). C-peptide-glucagon tests were performed yearly in duplicate after 2-3 days of temporary withdrawal of treatment. RESULTS - After 1 year the glucagon-stimulated C-peptide response was increased in the insulin-treated group by 0.14 ▒ 0.08 nmol/l, whereas it was decreased by 0.12 ▒ 0.08 nmol/l in the glibenclamide group, P < 0.02 for difference between groups. After 2 years, fasting insulin levels were higher after treatment withdrawal in the insulin-treated versus the glibenclamide-treated group (P = 0.02). HbA1c levels decreased significantly during the first year in both groups, however, at the end of the second year, HbA1c had deteriorated in the glibenclamide group (P < 0.01), but not in the insulin-treated group. The difference in evolution of HbA1c during the second year was significant between groups, P < 0.02 A questionnaire indicated no difference in well-being related to treatment. CONCLUSIONS - Early insulin versus glibenclamide treatment in type 2 diabetes temporarily prolongs endogenous insulin secretion and promotes better metabolic control.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Sundkvist, GöranLund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine(Swepub:lu)endo-gsu
(author)
-
Lager, I
(author)
-
Henricsson, M
(author)
-
Berntorp, KerstinLund University,Lunds universitet,Genomik, diabetes och endokrinologi,Forskargrupper vid Lunds universitet,Genomics, Diabetes and Endocrinology,Lund University Research Groups(Swepub:lu)endo-kbe
(author)
-
Fernqvist-Forbes, E
(author)
-
Steen, L
(author)
-
Westermark, Gunilla,1958-Linköpings universitet,Hälsouniversitetet,Cellbiologi(Swepub:liu)gunwe13
(author)
-
Westermark, P
(author)
-
Orn, T
(author)
-
Grill, Valdemar
(author)
-
Karolinska InstitutetInstitutionen för kliniska vetenskaper, Malmö
(creator_code:org_t)
Related titles
-
In:Diabetes Care: American Diabetes Association26:8, s. 2231-22370149-59921935-5548
Internet link
Find in a library
To the university's database
- By the author/editor
-
Alvarsson, M
-
Sundkvist, Göran
-
Lager, I
-
Henricsson, M
-
Berntorp, Kersti ...
-
Fernqvist-Forbes ...
-
show more...
-
Steen, L
-
Westermark, Guni ...
-
Westermark, P
-
Orn, T
-
Grill, Valdemar
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Endocrinology an ...
- Articles in the publication
-
Diabetes Care
- By the university
-
Linköping University
-
Lund University
-
Karolinska Institutet